About
About Guangdong Zhongsheng Pharmaceutical Co., Ltd
Guangdong Zhongsheng Pharmaceutical Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China. The company offers onradir, Leretevir, compound danshen, Cefixime Dispersible, Pyrazinamide, Ethamibutanol Hydrochloride, Ribavirin, loratadine, and isoniazid tablets; compound thromboplastin series, Zhong Sheng Wan series, and heat-clearing and dampness-removing granules products; NaoShuanTong, Cefadroxil, Rifampicin, and omeprazole enteric-coated capsules; carbocysteine, Ambroxol Hydrochloride, and Clomastine fumarate oral solutions; sucralfate oral suspension; reba pat film; and Azalastine Hydrochloride, Praprofen, Diquafosol Sodium, and Cyclosporine eye drops. It also focuses on the fields of respiratory antiviral, ophthalmology, cardiovascular and cerebrovascular endocrinology, anti-infection, digestion, and anti-allergy. Guangdong Zhongsheng Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Dongguan, China.
Visit company website
5 years, 5 months ago
Guangdong Zhongsheng Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 14.3% below its 200 day moving average.
From a valuation standpoint, the stock is 64.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.4.
Guangdong Zhongsheng Pharmaceutical Co., Ltd's total revenue sank by 14.3% to $525M since the same quarter in the previous year.
Its net income has increased by 65.5% to $110M since the same quarter in the previous year.
Finally, its free cash flow fell by 20.3% to $34M since the same quarter in the previous year.
Based on the above factors, Guangdong Zhongsheng Pharmaceutical Co., Ltd gets an overall score of 2/5.